1   
Release Date Title (Click to read)
Jan 19, 2011 Pernix™ Therapeutics and ParaPRO Receive FDA Approval of Natroba™ for Treatment of Head Lice
Feb 1, 2011 Pernix™ Therapeutics Appoints Joseph T. Schepers as Director of Investor Relations…
Mar 3, 2011 Pernix Therapeutics Provides Product Update
Mar 4, 2011 Pernix Therapeutics to Present at the Cowen & Company 31st Annual Health Care Conference
Mar 24, 2011 Pernix Therapeutics and SEEK Appoint J.P. Morgan to Auction Theobromine (BC1036) Asset
Mar 28, 2011 Pernix Therapeutics to Report 4th Quarter and Year End 2010 Financial Results on March 31, 2011
Mar 31, 2011 Pernix Therapeutics Holdings Reports Full Year And Fourth Quarter 2010 Financial Results
May 12, 2011 Pernix Therapeutics Holdings to Report First Quarter 2011 Financial Results on May 17, 2011
May 17, 2011 Pernix Therapeutics Holdings Reports First Quarter 2011 Financial Results
Jun 28, 2011 Pernix Therapeutics Added to Three Russell® Indexes
Jul 21, 2011 Pernix Announces Pricing of $28 Million Underwritten Registered Direct Offering of Common Stock
Aug 3, 2011 Pernix Therapeutics Holdings to Report Second Quarter 2011 Financial Results on August 16, 2011
Aug 15, 2011 Pernix Therapeutics and ParaPRO Announce Commercial Launch of Natroba™ For Treatment of Head Lice
Aug 16, 2011 Pernix Therapeutics Holdings Reports Second Quarter 2011 Financial Results
Aug 24, 2011 Pernix Therapeutics to Present at the Stifel Nicolaus Healthcare Conference
Aug 31, 2011 Pernix Therapeutics Appoints Steven A. Elms to Board of Directors
Nov 15, 2011 Pernix Therapeutics Holdings Reports Third Quarter 2011 Financial Results
Nov 21, 2011 Pernix Therapeutics to Present at the Piper Jaffray 23rd Annual Health Care Conference
Dec 6, 2011 Pernix Therapeutics Expands Senior Management Team to Support Continued Business Growth
Jan 23, 2012 Pernix Therapeutics Announces Agreement to License a New FDA-Approved Product to Treat Gastroenterology Disease
 1